Abstract
PRDM14 belongs to the PR domain-containing (PRDM) family. Although a precise understanding focused on the function of PRDM14 to maintain stemness and pluripotency in embryonic stem cells via epigenetic mechanisms, growing experimental evidence has been linked PRDM14 to human cancers. In adults, PRDM14 has low expression in human tissues. Aberrant PRDM14 expression is connected with various malignant histological types and solid cancers, where PRDM14 can act as a driver of oncogenic processes. Overexpression of RPDM14 enhanced cancer cells growth and reduced cancer cells sensitive to chemotherapeutic agents. Reducing the expression of PRDM14 in cancer cells can enhance the therapeutic sensitivity of drugs to cancer cells, suggesting that aberrant PRDM14 may have a carcinogenic characteristic in tumor therapy and as a new molecular target. This review summarizes the structure and oncogenic properties of PRDM14 in different malignancies and suggests that PRDM14 may be a potential therapeutic molecular target for tumor treatment.
Keywords: PRDM14, oncogene, chemotherapeutic resistance, PRDM family, molecular therapeutic target, cancer therapy.
Current Cancer Drug Targets
Title:PRDM14: A Potential Target for Cancer Therapy
Volume: 18 Issue: 10
Author(s): Mengting Ou, Shun Li and Liling Tang*
Affiliation:
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044,China
Keywords: PRDM14, oncogene, chemotherapeutic resistance, PRDM family, molecular therapeutic target, cancer therapy.
Abstract: PRDM14 belongs to the PR domain-containing (PRDM) family. Although a precise understanding focused on the function of PRDM14 to maintain stemness and pluripotency in embryonic stem cells via epigenetic mechanisms, growing experimental evidence has been linked PRDM14 to human cancers. In adults, PRDM14 has low expression in human tissues. Aberrant PRDM14 expression is connected with various malignant histological types and solid cancers, where PRDM14 can act as a driver of oncogenic processes. Overexpression of RPDM14 enhanced cancer cells growth and reduced cancer cells sensitive to chemotherapeutic agents. Reducing the expression of PRDM14 in cancer cells can enhance the therapeutic sensitivity of drugs to cancer cells, suggesting that aberrant PRDM14 may have a carcinogenic characteristic in tumor therapy and as a new molecular target. This review summarizes the structure and oncogenic properties of PRDM14 in different malignancies and suggests that PRDM14 may be a potential therapeutic molecular target for tumor treatment.
Export Options
About this article
Cite this article as:
Ou Mengting , Li Shun and Tang Liling*, PRDM14: A Potential Target for Cancer Therapy, Current Cancer Drug Targets 2018; 18 (10) . https://dx.doi.org/10.2174/1568009618666180430143055
DOI https://dx.doi.org/10.2174/1568009618666180430143055 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Current Signal Transduction Therapy Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Novel Non-Invasive Protein and Peptide Drug Delivery Approaches
Protein & Peptide Letters Hsp27 as a Therapeutic Target in Cancers
Current Drug Targets The Effect of Melatonin on Superoxide Dismutase and Glutathione Peroxidase Activity, and Malondialdehyde Levels in the Targeted and the Non-targeted Lung and Heart Tissues after Irradiation in Xenograft Mice Colon Cancer
Current Molecular Pharmacology Fungal Mediated Generation of Mammalian Metabolites of Fenofibrate and Enhanced Pharmacological Activity of the Main Metabolite Fenofibric Acid
Drug Metabolism Letters Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery Cancer Chemoprevention by Garlic and Its Organosulfur Compounds-Panacea or Promise?
Anti-Cancer Agents in Medicinal Chemistry Advancements in the Understanding of Paclitaxel Metabolism in Tissue Culture
Current Pharmaceutical Biotechnology Metal–Organic Framework (MOF)-based Nanomaterials for Biomedical Applications
Current Medicinal Chemistry Phytosterols and Triterpenoids for Prevention and Treatment of Metabolic-related Liver Diseases and Hepatocellular Carcinoma
Current Pharmaceutical Biotechnology Exploration of Chemical Space Based on 4-Anilinoquinazoline
Current Medicinal Chemistry 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Skin Regeneration: The Possibilities
Recent Patents on Regenerative Medicine Synthesis and Anti-cancer Activities of Apigenin Derivatives
Medicinal Chemistry The Evolutionary Tale and Future Directions of Aromatase Inhibitors in Breast Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Toxicity of Ionic Liquids Towards Mammalian Cell Lines
Current Organic Chemistry Targeting M3 Muscarinic Receptors for Colon Cancer Therapy
Current Molecular Pharmacology Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry Identification and Characterization of the Biosynthetic Gene Cluster of Thiolutin, a Tumor Angiogenesis Inhibitor, in Saccharothrix algeriensis NRRL B-24137
Anti-Cancer Agents in Medicinal Chemistry